| Document |
Document Title |
|
WO/2023/027082A1 |
The present invention addresses the problem of providing a hybrid liposome exosome or the like capable of delivering an active ingredient to a target cell at a higher concentration. This peptide-bound hybrid liposome exosome, which inc...
|
|
WO/2023/028542A1 |
Methods and compositions for stimulating hair growth are disclosed. Compositions for stimulating hair growth include two or more of hyaluronic acid, osteopontin, and another CD44 binding ligand. Methods for stimulating hair growth includ...
|
|
WO/2023/027950A1 |
Compositions and methods for the reproductive management of sheep and goats are provided. More particularly, methods for stimulating follicular maturation and/or synchronizing ovulation in sheep and goats are provided. In some embodiment...
|
|
WO/2023/024444A1 |
Disclosed in the present invention are an anti-MSLN monoclonal internalizing antibody, a preparation method therefor and an application thereof. The antibody comprises a heavy chain variable region and a light chain variable region; the ...
|
|
WO/2023/027098A1 |
The present invention provides: an anti-HBV agent that contains a substance that suppresses the expression or inhibits the activity of hypoxia-inducible factor prolyl hydroxylase (HIF-PH); a pharmaceutical composition for treating or pre...
|
|
WO/2023/027088A1 |
This composition for improving the drug sensitivity of an antibacterial drug to methicillin-resistant Staphylococcus aureus (MRSA) comprises at least one bacteriophage selected from the group consisting of the bacteriophage identified by...
|
|
WO/2023/024337A1 |
The use of a thiazolyldiazonaphthol compound represented by formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating glioblastoma (GBM), in formula I, R1, R2, R3, R4, R5, and R6 being selected fro...
|
|
WO/2023/025272A1 |
The present invention relates to a pharmaceutical composition, comprising a pharmaceutically active ingredient, glycerol, a sustained-release carrier, and a pharmaceutically acceptable solvent. The pharmaceutical composition is small in ...
|
|
WO/2023/027032A1 |
Provided are a self degradation-type CDK9 inhibitor prodrug and a liposome encapsulating same. The present invention pertains to a compound represented by formula (1), or a pharmaceutically acceptable salt thereof [in the formula, R1 rep...
|
|
WO/2023/027164A1 |
The present invention addresses the problem of providing an ROS production promoter. The present invention provides an ROS production promoter that contains an agent that recognizes a transferrin receptor.
|
|
WO/2023/023245A1 |
The present disclosure provides a method of treating hypercholesterolemia and other conditions related to PCSK9 activity, e.g. atherosclerosis, atherosclerotic cardiovascular disease, coronary heart disease, metabolic syndrome, acute cor...
|
|
WO/2023/021533A1 |
Disclosed is a composition comprising astaxanthin and ceramide for use in the treatment of keratosis pilaris, preferably keratosis pilaris alba.
|
|
WO/2023/019846A1 |
Provided are the use of cobra neurotoxin and a preparation thereof in the preparation of a drug for preventing and treating Parkinson's disease. Specifically provided are a new use of cobratide for treating Parkinson's disease and a new ...
|
|
WO/2023/021024A1 |
The present invention relates to the treatment of cancer by administering thermosensitive liposomes comprising doxorubicin. The liposome administration may preferably be combined with hyperthermia before, during and/or after the liposome...
|
|
WO/2023/023038A1 |
The present application provides pharmaceutical compositions and methods for treating diseases or disorders. The pharmaceutical composition comprises N-methyl-Daspartate receptor modulator and μ-opioid receptor modulator. The present ap...
|
|
WO/2022/047209A9 |
This invention relates to methods for selecting a treatment and optionally treating subjects with muscle-invasive bladder cancer based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
|
|
WO/2023/020291A1 |
The present invention relates to the combined use of: (a) a compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) PLD or a pharmaceutically acceptable salt thereof, for treating ovarian cancer.
|
|
WO/2023/021175A1 |
The present invention refers to a composition comprising R-Ketorolac, Bumetadine, at least one Cl- channels blocker and, optionally, Infliximab for use in the treatment of low- and high-grade glioma.
|
|
WO/2023/001264A9 |
An antibiotic pharmaceutical composition for intradermal or subcutaneous administration, comprising antibiotics and hyaluronidase. Also provided are a kit comprising the pharmaceutical composition, a method for preparing the kit, and the...
|
|
WO/2023/023377A1 |
The disclosure provides compositions, preparations, and methods comprising cell- derived vesicles induced using a blebbing agent from a hybridoma of a dendritic cell and a target cell, and uses thereof, including as a means to modulate a...
|
|
WO/2023/022141A1 |
Provided is a cancer therapeutic agent for cancer tissues including CD209 positive cells. This cancer therapeutic agent for cancer tissues including CD209 positive cells, comprises gel particles containing a modified polysaccharide inclu...
|
|
WO/2023/023629A1 |
Provided are methods and compositions for use in cancer immunotherapies. Exemplary compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In some embod...
|
|
WO/2023/023627A1 |
The invention provides polymeric H-NOX proteins for the preservation of organs for transplant. Methods and compositions comprising polymeric H-NOX proteins for the preservation of organs for transplant are also disclosed.
|
|
WO/2023/023527A1 |
Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.
|
|
WO/2023/023227A1 |
The present invention relates to methods, uses, and compositions for the treatment of Sickle cell disease (SCD), beta thalassemia (BT), sickle cell BT. More specifically, the invention concerns the treatment of patients having SCD, BT, o...
|
|
WO/2023/019259A1 |
Described herein, in part, are methods of treating cancer in patients in need thereof, comprising administering to the patient a VPS34 inhibitor and one or more additional therapeutic agents, such as a STING agonist.
|
|
WO/2023/017907A1 |
The present invention relates to a microneedle patch. The microneedle patch according to an embodiment of the present invention comprises: a base; and micro needles disposed at the surface of the base and containing a base material, an a...
|
|
WO/2023/016562A1 |
The present invention relates to a polycyclic compound and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula (I), wherein the definitions of each group and each substituent are...
|
|
WO/2023/018688A1 |
Disclosed herein are compositions and methods for treating an individual having a leukemia. In certain aspects, the methods may include administering an I0DVA1 compound and ponatinib to an individual in need thereof for treatment of a le...
|
|
WO/2023/017154A1 |
The present invention is related to compounds, methods, compositions and uses that are able to inhibit mitochondrial pyruvate carrier (MPC) activity and which are useful for immunotherapy, in particular T-cell therapies, immune check poi...
|
|
WO/2023/017000A1 |
This application relates to methods of treating and/or preventing cancer (e.g., non- small cell lung cancer, small cell lung carcinoma, colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer, biliary cancer and melanoma in s...
|
|
WO/2023/015526A1 |
The present disclosure provides a compound. The compound is a twin drug formed by a platinum drug and a small molecule drug that is covalently connected to the axial position of the platinum drug and has a negative immune modulation reli...
|
|
WO/2023/016129A1 |
Provided in the present invention are a new chimeric antigen receptor that specifically binds to EPHA2, and the use thereof.
|
|
WO/2023/017191A1 |
The invention relates to an interleukin-2/interleukin-receptor βγ(IL-2/IL-15Rβγ) agonist for use in treating cancer in a patient, wherein said IL-2/IL-15Rβγ agonist is administered in combination with a cytotoxic compound capable o...
|
|
WO/2023/018795A1 |
The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an NEP inhibitor or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for ...
|
|
WO/2023/015822A1 |
The present invention provides a hypoxia-triggered artificial transcription factor (HATF), and further provides a hypoxia-triggered transcription control system. The transcription control system comprises a nucleic acid sequence coding t...
|
|
WO/2023/018406A1 |
Embodiments of the present disclosure provide a biofield apparatus. The apparatus includes a first vial and a second vial configured to hold fluid for storing biofield information associated with a subject. The apparatus includes an inpu...
|
|
WO/2023/011076A1 |
Disclosed in the present invention are a multi-target complex of a loaded liposome and a drug-loaded platform containing same and an application. The multi-target complex of the loaded liposome contains: a stimulator of interferon genes ...
|
|
WO/2023/013627A1 |
The present invention addresses the problem of providing a disinfecting composition that, when an incise drape is placed on the skin surface on which the disinfecting composition has been applied, can reduce the risk of the incise drape ...
|
|
WO/2023/015146A2 |
Embodiments of the present disclosure provide systems and methods for a vertical take-off and landing craft. The system provides a craft capable of a vertical take-off and landing configuration and a horizontal thrust configuration. The ...
|
|
WO/2023/014062A1 |
Disclosed in the present invention are: a pharmaceutical composition for preventing or treating fibrotic diseases, comprising hyaluronan and proteoglycan link protein 1 (HAPLN1) or a gene encoding same as an active ingredient; and a meth...
|
|
WO/2023/012353A1 |
The invention relates to the use of selective estrogen receptor modulators (SERMs) for the therapeutic treatment of Batten Disease. Batten Disease is the common name for a group of recessively inherited fatal diseases of the nervous syst...
|
|
WO/2023/013763A1 |
The present invention provides a novel and effective cancer immunotherapeutic agent exhibiting a therapeutic effect against refractory cancers, particularly against cancers for which immune checkpoint inhibitors used as a monotherapy or ...
|
|
WO/2023/013719A1 |
There has been demand to identify miRNA that could be made to be involved in treatment and/or prevention in common across various cancer types from a variety of miRNA relating to cancer, and to provide a novel pharmaceutical composition ...
|
|
WO/2023/011488A1 |
The present invention relates to the field of medicine, and particularly relates to a pharmaceutical combination comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL inhibitor and one or more anticancer agents, and use of the combination for t...
|
|
WO/2023/013955A1 |
The present invention relates to a pharmaceutical composition for combined administration, comprising T-cell extracellular vesicles and an anticancer drug as active ingredients. By having confirmed that, when extracellular vesicles, whic...
|
|
WO/2023/012280A1 |
The present invention relates to the use of Colistin for reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), wherein said patients are infected with P. aeruginosa.
|
|
WO/2023/012244A1 |
The present invention provides a combination for simultaneous, separate or sequential therapy comprising a therapeutically effective amount of (a) one or more bile acids, bile salts or derivatives thereof; (b) a compound comprising a nic...
|
|
WO/2023/014817A1 |
The present invention features methods of treating a blood cancer (e.g., a lymphoma (e.g., MCL)) by administering, to a patient in need thereof, a therapeutically effective amount of (i) a BTK inhibitor, an isotopic form thereof, or a ph...
|
|
WO/2023/014022A1 |
The present invention relates to a pyrimidine derivative, a method for preparing same, and a pharmaceutical composition for preventing or treating cancer comprising same as an active ingredient. The pyrimidine derivative of the present i...
|
